ClinicalTrials.gg

Program

nalfurafine

Also written as “IMM02-KORA”, “Remitch®” and “Nalfurafine hydrochloride(MT-9938) 2.5μg”.

Its studies are mostly in Pruritus · Dyskinesias · Kidney Failure, Chronic, led by 6 companies.

Furthest: phase 3, since Mar 12, 20089 company-led studies, 1 open or runningNext primary completion: Dec 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Toray Industries30 open or runningphase 2since Mar 12, 2008Mar 12, 2008none ahead
SK Chemicals20 open or runningphase 3since Nov 23, 2010Nov 23, 2010none ahead
3SBio10 open or runningphase 3since Jan 26, 2021Jan 26, 2021none ahead
Acologix10 open or runningphase 3since Nov 17, 2008Nov 17, 2008none ahead
Immunis11 open or runningphase 1since Oct 15, 2026Oct 15, 2026Dec 30, 2027phase 1 · NCT07905976
Lunan Pharmaceutical Group10 open or runningno phasesince Mar 12, 2026Mar 12, 2026none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 12, 2008First study: phase 2 study in Pruritus With Chronic Liver DiseaseNew to Toray IndustriesToray Industries · NCT00638495 · 120 enrolled · Japan
  2. Nov 17, 2008Acologix's first study: phase 3 study in Uremic PruritusNew to AcologixAcologix · NCT00793156 · 350 enrolled
  3. Nov 23, 2010SK Chemicals's first study: phase 3 study in PruritusNew to SK ChemicalsSK Chemicals · NCT01513161 · 104 enrolled · Korea, Republic of
  4. Nov 23, 2010Phase 1 study in Kidney Failure, ChronicSK Chemicals · NCT01248650 · 16 enrolled · Korea, Republic of
  5. Aug 2, 2012Phase 2 study in PruritusToray Industries · NCT01660243 · 45 enrolled · United States
  6. Dec 13, 2016Phase 1 study in Uremic PruritusToray Industries · NCT03002233 · 23 enrolled · Bulgaria, Germany
  7. Jan 26, 20213SBio's first study: phase 3 study in Uremic PruritusNew to 3SBio3SBio · NCT04728984 · 135 enrolled · China
  8. Mar 12, 2026Lunan Pharmaceutical Group's first study: no phase study in PruritusNew to Lunan Pharmaceutical GroupLunan Pharmaceutical Group · NCT07478133 · 72 enrolled · China
  9. Oct 15, 2026Immunis's first study: phase 1 study in Dyskinesia, Drug-InducedNew to ImmunisImmunis · NCT07905976 · 15 planned

Ahead

  1. Dec 30, 2027Primary completion: phase 1 study in Dyskinesia, Drug-InducedImmunis · NCT07905976

TargetBeta

OPRK1 →read by rule
“Kappa opioid receptor agonist”ChEMBL 37, by rule

Other programs on OPRK1

ProgramCompanyFurthest phaseStudies
Naltrexoneruleorexigen-therapeutics-incphase 442
nalmefeneruleH. Lundbeckphase 420
NalbuphineruleTrevi Therapeuticsphase 420
cebranopadolruleTris Pharmaphase 318
AticaprantruleJohnson & Johnsonphase 313
asimadolineruletioga-pharmaceuticalsphase 36
icalcaprantAbbViephase 26

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07905976Dyskinesia, Drug-Induced1Not yet recruitingImmunisDec 30, 202715
NCT07478133Pruritus · China–CompletedLunan Pharmaceutical GroupJul 14, 202372
NCT04728984Uremic Pruritus · China3UNKNOWN3SBioJun 30, 2021135
NCT03002233Uremic Pruritus · Bulgaria, Germany1CompletedToray IndustriesJul 201723
NCT01660243Pruritus · United States2TerminatedToray IndustriesMar 201445
NCT01513161Pruritus · Korea, Republic of3CompletedSK ChemicalsOct 2009104
NCT01248650Kidney Failure, Chronic · Korea, Republic of1CompletedSK ChemicalsDec 200816
NCT00793156Uremic Pruritus3UNKNOWNAcologixDec 2010350
NCT00638495Pruritus With Chronic Liver Disease · Japan2CompletedToray IndustriesDec 2009120

How it is read

Names in the registry

  • “IMM02-KORA”, 1 entry
  • “Remitch®”, 1 entry
  • “Nalfurafine hydrochloride(MT-9938) 2.5μg”, 1 entry
  • “Nalfurafine hydrochloride(MT-9938) 5μg”, 1 entry
  • “Nalfurafine hydrochloride(MT-9938) 10μg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.